MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

BACKGROUND: MYC is one of the most frequently altered driver genes in triple-negative breast cancer (TNBC). The aim of this study was to evaluate targeting MYC for the treatment of TNBC. METHODS: The anti-proliferative and apoptosis-inducing effects of the recently discovered MYC inhibitor, MYCi975...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Minhong, O’Grady, Shane, Crown, John, Duffy, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374613/
https://www.ncbi.nlm.nih.gov/pubmed/35908121
http://dx.doi.org/10.1007/s10549-022-06673-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374613/
https://www.ncbi.nlm.nih.gov/pubmed/35908121
http://dx.doi.org/10.1007/s10549-022-06673-6

Ejemplares similares